Should I Buy OMER? OMER 2026 Analysis

Should You Buy Omeros Corp (OMER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

11.810

1 Day change

-6.79%

52 Week Range

17.650

Analysis Updated At

2026/01/26

Omeros Corp (OMER) is not a strong buy for a beginner, long-term investor at the moment. While there are positive catalysts such as hedge fund buying and a favorable analyst upgrade, the technical indicators, weak financial performance, and lack of recent congress trading or news suggest that it is better to wait for more clarity or stronger signals before investing.

Technical Analysis

The MACD histogram is negative (-0.388) and contracting, indicating bearish momentum. RSI is neutral at 34.806, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level (12.712) and closer to the support level (S1: 11.669), suggesting potential downside risk in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds are heavily buying, with a 185085.19% increase in buying activity over the last quarter. Analysts have raised the price target significantly to $40, citing the approval of Yartemlea as a critical inflection point.

Neutral/Negative Catalysts

The company's financial performance is weak, with declining net income (-4.08% YoY) and EPS (-16.07% YoY). There is no recent congress trading data or news to act as a catalyst. Technical indicators do not support a strong upward trend.

Financial Performance

In Q3 2025, revenue remained flat at $0, net income dropped to -$30.92M (-4.08% YoY), and EPS fell to -$0.47 (-16.07% YoY). Gross margin also remained at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright upgraded the price target to $40 from $20, maintaining a Buy rating. The approval of Yartemlea is seen as a critical milestone, with an 80% probability of success in the U.S. and a high pricing model of $150K per patient.

4 Analyst Rating

Wall Street analysts forecast OMER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 43.67 USD with a low forecast of 36 USD and a high forecast of 55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 12.670

Low

Averages

43.67

High

Current: 12.670

Low

Averages

43.67

High

H.C. Wainwright

Brandon Folkes

maintain

$20 -> $40

AI Analysis

2026-01-08

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$20 -> $40

AI Analysis

2026-01-08

maintain

Reason

H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Omeros to $40 from $20 and keeps a Buy rating on the shares. The firm cites the approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy for the target boost. The analyst views the approval as a "critical inflection point" for Omeros.

H.C. Wainwright

Buy

maintain

$20

2025-12-24

Reason

H.C. Wainwright

Price Target

$20

2025-12-24

maintain

Buy

Reason

H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant validation" of Omeros value. H.C. Wainwright's current model assumed an 80% probability of success for Yartemlea in the U.S., and pricing of $150K per patient.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OMER

Unlock Now

OMER Should I Buy

OMER Should I Buy

Should You Buy Omeros Corp (OMER) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch